Posted by Michael Wonder on 02 Dec 2019
China updates drug reimbursement list, agrees price cuts
2 December 2019 - Drugs added include AbbVie's Humira and Roche's Perjeta.
Chinese regulators have added 70 new medicines to the country’s National Reimbursement Drug List (NRDL), and has agreed an average of 61% in price cuts with pharma companies.
The key drugs which have been added to the list include AbbVie’s blockbuster drug Humira (adalimumab), Novartis’ dermatitis drug Xolair (omalizumab) and Roche’s HER2 breast cancer treatment Perjeta (petuzumab).
